Rice Hall James & Associates LLC Purchases 21,022 Shares of Prestige Consumer Healthcare Inc. $PBH

Rice Hall James & Associates LLC boosted its position in Prestige Consumer Healthcare Inc. (NYSE:PBH) by 4.2% in the first quarter, HoldingsChannel.com reports. The institutional investor owned 521,622 shares of the company’s stock after purchasing an additional 21,022 shares during the period. Prestige Consumer Healthcare makes up approximately 1.7% of Rice Hall James & Associates LLC’s holdings, making the stock its 12th largest holding. Rice Hall James & Associates LLC’s holdings in Prestige Consumer Healthcare were worth $30,917,000 at the end of the most recent reporting period.

Several other hedge funds have also recently made changes to their positions in the company. UMB Bank n.a. raised its stake in shares of Prestige Consumer Healthcare by 110.1% in the fourth quarter. UMB Bank n.a. now owns 418 shares of the company’s stock valued at $26,000 after buying an additional 219 shares during the period. Bayforest Capital Ltd bought a new position in shares of Prestige Consumer Healthcare during the 4th quarter worth $29,000. Torren Management LLC bought a new position in shares of Prestige Consumer Healthcare during the 4th quarter worth $35,000. Caitong International Asset Management Co. Ltd increased its holdings in Prestige Consumer Healthcare by 69.8% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 574 shares of the company’s stock worth $35,000 after acquiring an additional 236 shares during the last quarter. Finally, Danske Bank A S purchased a new stake in Prestige Consumer Healthcare in the 3rd quarter worth about $37,000. 99.95% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

PBH has been the topic of a number of research reports. Oppenheimer cut Prestige Consumer Healthcare from an “outperform” rating to a “market perform” rating in a research note on Thursday, May 14th. Canaccord Genuity Group cut their target price on shares of Prestige Consumer Healthcare from $86.00 to $72.00 and set a “buy” rating for the company in a research report on Friday, May 15th. Zacks Research downgraded shares of Prestige Consumer Healthcare from a “hold” rating to a “strong sell” rating in a research note on Monday, May 18th. Finally, Weiss Ratings lowered shares of Prestige Consumer Healthcare from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Thursday, June 25th. Two equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $70.75.

Insider Buying and Selling

In other Prestige Consumer Healthcare news, VP Jeffrey Zerillo sold 1,207 shares of the firm’s stock in a transaction on Tuesday, May 5th. The shares were sold at an average price of $54.99, for a total value of $66,372.93. Following the completion of the transaction, the vice president directly owned 42,820 shares of the company’s stock, valued at $2,354,671.80. This trade represents a 2.74% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 1.50% of the stock is currently owned by insiders.

Prestige Consumer Healthcare Trading Up 1.5%

Shares of PBH opened at $49.67 on Friday. Prestige Consumer Healthcare Inc. has a twelve month low of $42.62 and a twelve month high of $77.03. The stock has a market cap of $2.35 billion, a PE ratio of 12.70, a P/E/G ratio of 1.60 and a beta of 0.35. The company has a quick ratio of 2.25, a current ratio of 3.57 and a debt-to-equity ratio of 0.54. The business’s 50-day moving average price is $47.94 and its 200-day moving average price is $56.91.

Prestige Consumer Healthcare (NYSE:PBH) last released its quarterly earnings data on Wednesday, May 13th. The company reported $1.23 EPS for the quarter, missing analysts’ consensus estimates of $1.39 by ($0.16). Prestige Consumer Healthcare had a net margin of 17.48% and a return on equity of 11.54%. The firm had revenue of $281.62 million during the quarter, compared to the consensus estimate of $293.64 million. During the same quarter last year, the business posted $1.32 earnings per share. Prestige Consumer Healthcare’s revenue was down 5.0% compared to the same quarter last year. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.420-4.510 EPS. On average, equities analysts forecast that Prestige Consumer Healthcare Inc. will post 4.45 EPS for the current fiscal year.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).